Skip to main content
. 2024 May 28;76:103756. doi: 10.1016/j.breast.2024.103756

Fig. 2.

Fig. 2

Treatment of ER-positive/HER2-negative ABC

Legend: ABC, advanced breast cancer; AI, aromatase inhibitor; CDK, cyclin-dependent kinase; DFI, disease-free interval; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PIK3CA, phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha. a Rechallenge with a taxane or anthracycline is possible if cumulative dose not reached and DFI ≥12 months.